Latest news newssearch boxGO 23 Jul 2020 Idorsia announces financial results for the first half 2020 16 Jul 2020 Idorsia establishes US commercial operations and leadership team 06 Jul 2020 Idorsia announces positive results in the second Phase 3 study of daridorexant 20 May 2020 Idorsia successfully completes the offering of new shares thereby securing funding for the company’s growth plan 19 May 2020 Idorsia launches an offering of new shares to fund the company’s growth plan 13 May 2020 Idorsia holds its third Annual General Meeting of Shareholders 12 May 2020 Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy 23 Apr 2020 Idorsia announces financial results for the first quarter 2020 20 Apr 2020 Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia 02 Apr 2020 Idorsia issues Notice of the 2020 Annual General Meeting of Shareholders 19 Mar 2020 Janssen announces submission of New Drug Application to the U.S. FDA for ponesimod for treatment of adults with relapsing multiple sclerosis 04 Mar 2020 Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis 06 Feb 2020 Idorsia announces financial results for 2019 – clinical programs advanced markedly – approaching first key results 10 Jan 2020 Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy 05 Dec 2019 Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan 19 Nov 2019 Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel 11 Nov 2019 Encouraging Phase 2 data on cenerimod – Idorsia's S1P1 receptor modulator currently investigated for SLE – presented at ACR 2019 22 Oct 2019 Idorsia announces financial results for the first nine months of 2019 02 Oct 2019 Data on cenerimod – Idorsia's S1P1 receptor modulator – will be presented at the ACR / ARP Annual Meeting 2019 11 Sep 2019 Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis 1 2 3 4
